Menotropins
drugOn this page
Also known as FollotropinFSHGynogen hpHMGHuman follicle stimulating hormoneHumegonHumogMenopurMenotrophinMenotropins (fsh;lh)MerionalNormegonPergonalPergonal low lhRepronex
Summary
Menotropins (CHEMBL2108427) is an approved protein targeting FSHR; indicated across 8 conditions including infertility disorder and polycystic ovary syndrome.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- Targets: 1 (FSHR)
- Indications: 8 conditions
- Clinical trials: 46
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108427 |
| Name | Menotropins |
| Type | Protein |
| Max phase | 4 |
Also known as: Follotropin, FSH, Gynogen hp, HMG, Human follicle stimulating hormone, Humegon, Humog, Menopur, Menotrophin, Menotropins, Menotropins (fsh;lh), Merional
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| FSHR | FSH receptor | Agonist | 0% | P23945 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): FSHR.
Top Reactome pathways
2 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Hormone ligand-binding receptors | 1 | FSHR |
| G alpha (s) signalling events | 1 | FSHR |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| primary ovarian follicle growth | 1 |
| regulation of systemic arterial blood pressure | 1 |
| G protein-coupled receptor signaling pathway | 1 |
| adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 |
| adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | 1 |
| phospholipase C-activating G protein-coupled receptor signaling pathway | 1 |
| spermatogenesis | 1 |
| female gamete generation | 1 |
| locomotory behavior | 1 |
| gonad development | 1 |
| male gonad development | 1 |
| female gonad development | 1 |
| hormone-mediated signaling pathway | 1 |
| intracellular water homeostasis | 1 |
| regulation of platelet-derived growth factor receptor signaling pathway | 1 |
Indications & clinical
Indications
8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| infertility disorder | 3 | MONDO:0005047 | EFO:0000545 |
| polycystic ovary syndrome | 3 | MONDO:0008487 | EFO:0000660 |
| hypogonadism | 3 | MONDO:0002146 | MONDO:0002146 |
| spermatogenic failure | 2 | MONDO:0004983 | EFO:0000279 |
| Kallmann syndrome | 2 | MONDO:0018800 | MONDO:0018800 |
| female infertility | 1 | MONDO:0021124 | EFO:0008560 |
| gonadal disorder | 1 | MONDO:0002259 | MONDO:0002259 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 46.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 22 |
| PHASE4 | 13 |
| PHASE3 | 9 |
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00257556 | PHASE4 | COMPLETED | A Study of the Efficacy and Safety of Highly Purified Menotrophin Versus Recombinant Follitropin Alfa |
| NCT01225835 | PHASE4 | COMPLETED | Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF) |
| NCT01250821 | PHASE4 | COMPLETED | Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility |
| NCT01365936 | PHASE4 | COMPLETED | hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF |
| NCT01403532 | PHASE4 | COMPLETED | Sequential Therapy for Hypogonadotropic Hypogonadism |
| NCT01417195 | PHASE4 | COMPLETED | Menopur Mixed Protocol |
| NCT01783301 | PHASE4 | COMPLETED | Anti-Mullerian Hormone (AMH) Versus Antral Follicle Count (AFC) Guided rFSH Dosing Study |
| NCT02069808 | PHASE4 | COMPLETED | Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation |
| NCT02412904 | PHASE4 | COMPLETED | Randomized Controlled Trial Comparing Embryonic Quality in rFSH Versus hMG in IVF Protocol With GnRH Antagonist |
| NCT02437032 | PHASE4 | COMPLETED | Gonadotropin Type in Ovarian Stimulation |
| NCT02741154 | PHASE4 | COMPLETED | Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI |
| NCT04157725 | PHASE4 | UNKNOWN | Mild Stimulation Protocol Using Clomiphene Citrate for Women With PCOS Undergoing in Vitro Fertilization |
| NCT04385342 | PHASE4 | UNKNOWN | FSH Followed by HMG vs FSH Plus HMG in IVF |
| NCT07340827 | PHASE3 | RECRUITING | A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) |
| NCT00696878 | PHASE3 | COMPLETED | Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714) |
| NCT00971152 | PHASE3 | COMPLETED | Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle |
| NCT01312766 | PHASE3 | COMPLETED | Safety and Efficacy Study in in Vitro Fertilisation (IVF) Patients |
| NCT02304107 | PHASE3 | COMPLETED | Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome. |
| NCT02304536 | PHASE3 | UNKNOWN | Comparison Between Laparoscopic Ovarian Diathermy and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome. |
| NCT02461173 | PHASE3 | UNKNOWN | Stimulated Intrauterine Insemination Cycles and Unstimulated Intrauterine Insemination Cycles in Couples With Unexplained Infertility |
| NCT02469805 | PHASE3 | UNKNOWN | Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Couples With Mild Male Factor Infertility |
| NCT02470169 | PHASE3 | UNKNOWN | Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Women With Endometriosis |
| NCT02544191 | PHASE2 | UNKNOWN | GnRHa Combined With hCG and hMG for Treatment of Patients With Non-obstructive Azoospermia |
| NCT02510534 | PHASE1 | TERMINATED | Effect of Luteal Progesterone Support on Pregnancy Rates With Combined Clomid/ Gonadotropin & IUI |
| NCT06803199 | Not specified | RECRUITING | Effects of LH and FSH on Metabolic Regulation in Cumulus Cells |
| NCT07568574 | Not specified | ENROLLING_BY_INVITATION | Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes |
| NCT07569939 | Not specified | NOT_YET_RECRUITING | Evaluation of Treatments for Sore Throat Associated With Acute Pharyngitis and/or Viral Tonsillitis |
| NCT00702234 | Not specified | COMPLETED | Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715) |
| NCT01354834 | Not specified | COMPLETED | Assessment of the Effectiveness of Menopur in Intrauterine Insemination |
| NCT01569945 | Not specified | COMPLETED | Hormonal Stimulation in IUI Treatment: Is Clomifen Combined With Ethinyl Estradiol Better, Worse or Equal to Menopur |
| NCT01669291 | Not specified | COMPLETED | Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation |
| NCT01810601 | Not specified | COMPLETED | Effect of Ultrasound Guided Embryo Transfer on Pregnancy Rates |
| NCT02322398 | Not specified | COMPLETED | Ovarian Stimulation With Recombinant Gonadotropins vs. Human Menopausal Gonadotropin in In Vitro Fertilization |
| NCT02681536 | Not specified | UNKNOWN | Miniflare Versus Long Protocol in Poor Responders |
| NCT02775877 | Not specified | UNKNOWN | Letrozole and Sequential Clomiphene to Improve the Outcome of Embryo Transfer |
| NCT02835469 | Not specified | COMPLETED | A Study on Efficacy and Safety of Menopur® Multidose in Korean Female Patients With Infertility |
| NCT02865681 | Not specified | COMPLETED | Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization |
| NCT02935335 | Not specified | COMPLETED | A Study to Measure Relationship Between Antimüllerian Hormone and Initial Dose of Menopur® |
| NCT03098199 | Not specified | COMPLETED | AMH and Dosing Regimens for Initial IVF Stimulation Protocols |
| NCT04193930 | Not specified | WITHDRAWN | Different Protocols in Ovarian Stimulation in Intracytoplasmic Sperm Injection Cycles |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
1 molecules share ≥1 primary target. Top 1 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| Yohimbine | PubChem | Approved | FSHR |
Related Atlas pages
- Genes: FSHR
- Diseases: infertility disorder, polycystic ovary syndrome, hypogonadism
- Drugs: Yohimbine